Advertisements

Levofloxacino

Quick links to important sections

Levofloxacino

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Levofloxacino

Quick Facts

Property Description
Active ingredient Levofloxacin
Pharmacological class Fluoroquinolone antibiotic (Third-generation)
Origin Synthetic (Chemically derived)
Primary action Bactericidal (Kills bacteria)
Differentiating factor Enhanced Gram-positive activity (Respiratory quinolone)

Identity and Pharmacological Classification of Levofloxacino

Levofloxacino is a potent, synthetic medicine classified as a fluoroquinolone antibiotic, recognized for its broad-spectrum antibacterial activity. The medication’s core identity stems from its single active ingredient, Levofloxacin, which is chemically the purified L-isomer component of the older drug Ofloxacin. This specific chemical structure is clinically recognized for contributing to the compound's enhanced potency against key respiratory pathogens, such as Streptococcus pneumoniae. This distinction is why it is often categorized as a respiratory quinolone.

Composition, Origin, and Available Forms

Levofloxacin is utilized as a single active ingredient and is stereochemically stable, meaning it retains its active form post-administration. To facilitate delivery as a systemic agent throughout the body, Levofloxacino is available in multiple dosage form(s) to suit different route(s) of administration. These preparations include the oral tablet and oral solution, facilitating convenient once-daily dosing, as well as the sterile injection solution for intravenous use. The drug's availability in both oral and IV forms confirms its utility across various clinical settings.

General Purpose: Action Against Bacterial Infection

The general purpose of Levofloxacino is to resolve illness by definitively killing susceptible microbes, functioning as a powerful bactericidal agent. This action is achieved by interfering directly with the pathogen’s essential genetic processes: Levofloxacin inhibits the critical bacterial enzymes DNA gyrase and topoisomerase IV. Consequently, the medicine is employed broadly as an antibacterial agent to overcome established systemic bacterial infections, with clinical literature supporting its efficacy for common uses like treating certain types of bacterial pneumonia and complicated urinary tract infections.

Regulatory References

  1. Levofloxacin - StatPearls (NIH)
Advertisements

What side effects are possible with Levofloxacino?

Possible Side Effects and Safety Information

The safety profile of Levofloxacino is structured by authoritative government regulatory agencies, highlighting both common and serious adverse reactions.


Serious and Disabling Adverse Reactions

Official regulatory documents emphasize the risk of disabling and potentially irreversible serious adverse reactions that can affect multiple body systems, sometimes occurring together. These risks include:

  • Tendinitis and Tendon Rupture: Inflammation or tearing of tendons, most frequently the Achilles, which may be delayed for months after treatment is stopped. The risk is higher in older patients (60 years of age) and those using systemic corticosteroids.
  • Peripheral Neuropathy: Nerve damage in the arms or legs, leading to pain, burning, tingling, or numbness, which may become permanent.
  • Central Nervous System (CNS) Effects: Reactions such as convulsions, anxiety, confusion, depression, hallucinations, and suicidal thoughts or actions.
  • Aortic Aneurysm and Dissection: An increased risk of tears or bulges in the aorta, particularly in older patients or those with a history of hypertension.

Other Clinically Significant Risks

Regulatory safety information details other serious events categorized by the system affected:

  • Cardiac: QT interval prolongation and the risk of a severe abnormal heart rhythm (Torsade de Pointes).
  • Hepatotoxicity: Severe, sometimes fatal, liver damage.
  • Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis, Stevens-Johnson Syndrome) that may occur after the first dose.
  • Blood Glucose: Disturbances in blood sugar levels, including severe hypoglycemia.
  • Myasthenia Gravis: Potential for exacerbation of muscle weakness in patients with this condition.

Safety-Related Restrictions

Due to the seriousness of these potential adverse reactions, official regulatory documents stipulate that Levofloxacino should be reserved for use in patients who have no alternative treatment options for certain infections, such as acute bacterial sinusitis or uncomplicated urinary tract infections. Use must be discontinued immediately at the first sign of a serious adverse reaction.

Advertisements

Overdose and Emergency Response

Levofloxacino Overdose and when to seek help

Overdosage with Levofloxacino is documented in regulatory labeling to present with pronounced manifestations primarily affecting the Central Nervous System (CNS) and the Cardiovascular System. Officially documented signs of acute overexposure include seizures (convulsions), tremor, confusion, and hallucinations, alongside exacerbated gastrointestinal symptoms. Severe outcomes officially cited include the potential for Prolongation of the QT interval and the development of the life-threatening ventricular arrhythmia Torsade de pointes, which also poses a risk of circulatory collapse.

When to Seek Urgent Help

Any suspected overdosage requires the patient to seek immediate medical attention or contact emergency services without delay. This urgent action is mandated due to the severity of the documented CNS and cardiac risks.

Management and Monitoring

According to official regulatory documents, no specific antidote is known for Levofloxacino overdose. Management is specified strictly as symptomatic and supportive treatment. Close observation is essential, which includes mandated ECG monitoring to observe for QT interval changes. Procedures to prevent further absorption, such as gastric emptying or the use of activated charcoal, may be considered. Furthermore, patients with impaired renal function are noted to be at increased risk of drug accumulation, potentially escalating the severity of the overdose.

Advertisements

Therapeutic Uses of Levofloxacino

Quick Facts: Therapeutic Areas

  • Respiratory Support: May be considered for community-acquired pneumonia and acute bacterial sinusitis.
  • Systemic Care: Utilized in the management of complicated urinary tract infections and acute pyelonephritis.
  • Skin and Structure: Employed in therapeutic regimens for complicated and uncomplicated skin and skin structure infections.

Levofloxacino is a medication used to support the management of various bacterial infections in adults. Its therapeutic domains include respiratory tract concerns, such as certain types of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The medication may be a treatment option for individuals with acute bacterial sinusitis when other, less systemic, options are not appropriate.

It is also utilized within a comprehensive care strategy for infections affecting the urinary system, specifically complicated urinary tract infections and acute pyelonephritis. Furthermore, Levofloxacino is a component of the treatment protocol for complicated and uncomplicated skin and skin structure infections. For specific, severe public health threats, such as post-exposure prophylaxis for inhalational anthrax and the treatment of plague, this medication is indicated.

Its use is intended for treating infections caused by designated susceptible bacteria and should be reserved for cases where the infection is proven or strongly suspected to be bacterial.

Advertisements

Eligibility and Restrictions for Use

Levofloxacino eligibility is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations. The medication is approved for use in adult patients (ge 18 years of age) for general indications. Use in children or growing adolescents is generally contraindicated for common infections due to the risk of joint damage, though the FDA approves restricted use for specific, life-threatening public health threats like anthrax and plague in patients ge 6 months of age.

Contraindicated Populations Condition-Specific Restrictions
Hypersensitivity to quinolones Patients with renal impairment require mandated dosage adjustment.
History of tendon disorders related to any fluoroquinolone Older patients (ge 60 years) have an increased risk of tendon rupture and require caution.
Patients with epilepsy or myasthenia gravis Organ transplant recipients also carry an elevated risk of tendon injury.
Pregnancy and breastfeeding Patients with risk factors for QT interval prolongation require caution.

The official documents establish a categorical exclusion for individuals with certain pre-existing conditions and physiological states. Use in older adults and patients with impaired kidney function is permitted but requires special consideration to manage increased regulatory risk.

Advertisements

What should I know about interactions with other medicines?

The official prescribing information for Levofloxacino establishes several clinically relevant interaction domains that define restrictions and required monitoring, based on formal regulatory documentation.

Interaction Category Interacting Agents / Classes Regulatory Constraint
Formal Contraindication Dronedarone, Pimozide, Thioridazine Co-administration is prohibited due to the risk of additive QTc prolongation.
Absorption Interference Antacids, Sucralfate, Iron Salts, Zinc Salts, Buffered Didanosine Oral products containing these multivalent cations must be separated by at least two hours from the Levofloxacino dose.
Drug Clearance Alteration Probenecid, Cimetidine Co-administration reduces the renal clearance of Levofloxacino, resulting in increased systemic exposure.
Pharmacodynamic Risk Warfarin, Antidiabetic Agents, Theophylline, NSAIDs Requires close monitoring for enhanced anticoagulant effects (Warfarin) or disturbances in blood glucose (Antidiabetic Agents).

Levofloxacino absorption is significantly reduced when taken simultaneously with products containing multivalent cations. This pharmacokinetic interference requires a mandatory administrative rule: the oral dose must be separated from these products by at least two hours. Further pharmacokinetic interactions occur with Probenecid and Cimetidine, which decrease the drug's renal clearance. The interaction profile also encompasses pharmacodynamic concerns, including the need for careful blood glucose monitoring with antidiabetic agents, and the risk of enhanced anticoagulant effects when co-administered with Vitamin K Antagonists such as Warfarin. Additionally, specific caution regarding interaction severity is noted for geriatric patients receiving concomitant corticosteroids, due to the increased risk of tendinopathy.

Advertisements

Mechanism of Action

Dual Interference with Bacterial DNA Structure

Levofloxacino exerts a bactericidal action by directly targeting two critical bacterial enzymes: DNA gyrase (Topoisomerase II) and topoisomerase IV. The molecule acts as a topoisomerase poison, binding to the enzyme-DNA complex to prevent the crucial re-ligation of the cut DNA strand, thereby locking the bacterial cell's genetic material in a state of irreparable damage.

The Cascade of Fatal Cellular Events

This dual molecular trapping initiates two lethal cascades: preventing the necessary unwinding of DNA for replication and blocking the segregation of chromosomes during cell division. The resulting accumulation of DNA double-strand breaks overwhelms the bacteria's repair mechanisms, triggering swift cellular death. This action results in concentration-dependent killing and physical eradication of susceptible microbial populations.

Mechanistic Limitations: Evasion of Binding

The intended mechanism is compromised when bacteria acquire mutations in the Quinolone Resistance-Determining Regions (QRDR), which physically alter the binding sites on the target enzymes. This target-mediated resistance, alongside the activity of drug-expelling efflux pumps, lowers the drug's affinity or effective intracellular concentration. This prevents the intended bactericidal effect, allowing the targeted bacterial population to survive and continue replicating.

Advertisements

Dosage and Administration Information

Levofloxacino is an antibacterial agent approved for systemic administration in adults via the oral route (tablets and oral solution) and the intravenous (IV) route (injection/infusion). The parenteral and oral forms are considered bioequivalent, allowing for a seamless transition between the two at the same dosage.

Official Dosing and Frequency

Adult dosing typically follows a once-daily (every 24 hours) schedule, with standard daily doses ranging from 250 mg to 750 mg. The total course of therapy is defined by the specific infection and may range from a short, 3-day regimen for uncomplicated infections to an extended 60-day or 8-week regimen for conditions like post-exposure anthrax prophylaxis.

Administration Route Dosing Frequency Course Duration Range (Adults)
Oral or IV Once Daily 3 days to 8 weeks

Administration Conditions

Oral Administration: Tablets may be taken with or without food. The oral solution should be taken on an empty stomach, either 1 hour before or 2 hours after a meal. To ensure proper absorption, oral formulations must be taken at least two hours before or two hours after products containing multivalent cations, such as iron salts, zinc salts, or magnesium/aluminum-containing antacids.

Intravenous Administration: The IV solution must be administered via slow infusion only. A 250 mg dose should be infused over at least 30 minutes, while 500 mg and 750 mg doses require an infusion time of at least 60 minutes.

Population-Specific Rules

Renal Impairment: Dose adjustment is mandatory for adult patients with reduced renal function (creatinine clearance < 50 mL/min). The dosing frequency or amount must be reduced, based on the degree of impairment. Hepatic impairment does not require dose adjustment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levofloxacino

Evidence for Use in Respiratory Infections (Pneumonia and Bronchitis)

Research exploring how symptoms change over time in patients with Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) was evaluated in largely Randomized Controlled Trials (RCTs). These studies were designed as Active-Controlled Trials to compare the measured outcomes against other established antibiotics. Research monitored key markers such as the measurement of changes in clinical signs and symptoms and the clearance of the target bacteria. Findings describe patterns observed across treatment groups, but many trials used restrictive enrollment criteria, meaning the results apply primarily to the populations studied.

Evidence for Use in Urinary Tract and Skin Infections

Levofloxacino was studied for conditions associated with acute or disruptive episodes, specifically Complicated Urinary Tract Infections (cUTI) and Skin and Skin Structure Infections (SSSI). Research examined the drug in adults using comparative clinical trials to monitor outcomes linked to inflammatory or irritative states associated with the infection. Studies reported patterns related to the measured frequency of microbiological clearance. Evidence quality varies across studies, and the long-term effects are not fully established in the broad evidence base.

Evidence for Public Health & Specialized Indications (Anthrax and Plague)

For Anthrax and Plague, direct human efficacy studies could not be conducted for ethical reasons. Efficacy research relied on Animal Efficacy Challenge Studies (e.g., non-human primates) to monitor the frequency of survival events. Pharmacokinetic (PK) research was conducted in human volunteers to ensure appropriate drug concentration levels. The key research limitation is the absence of direct human efficacy data, meaning the evidence is established via the Animal Rule, which relies on non-human data.

Summary of Research Gaps and Uncertainties

Studies have observed responses over defined time intervals, but follow-up durations were limited to the acute phase for most approved uses. There is limited information for long-term outcomes, and data for certain special groups remain insufficient, such as older adults with multiple chronic conditions. The research base describes group patterns but indicates areas where further research is needed to fully characterize the treatment's profile.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Levofloxacino (FAQ)


Q: How is Levofloxacino different from Ciprofloxacin?

Both medicines belong to the fluoroquinolone class of antibiotics. Regulatory classifications note that Levofloxacino is often described as having enhanced activity against certain Gram-positive respiratory pathogens, such as Streptococcus pneumoniae. Ciprofloxacin is generally characterized as being active against a wider range of Gram-negative pathogens.


Q: Are the side effects of Levofloxacino common or rare?

Official documents classify side effects by how often they occur. Very common effects are those that may affect more than 1 in 10 people, and these can include stomach upset (nausea), headache, diarrhea, and trouble sleeping (insomnia). Other adverse events are classified as common, uncommon, or rare based on frequency data.


Q: Does Levofloxacino cause sun sensitivity?

Yes, Levofloxacino is associated with the risk of photosensitivity. This means the skin can become more sensitive to natural sunlight or artificial ultraviolet light. Official warnings describe the use of protective measures, such as wearing sunscreen and protective clothing, as necessary during treatment.


Q: What happens if I miss taking a dose of Levofloxacino?

Official patient instructions generally advise that if a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped entirely. This approach is intended to maintain the proper dosing schedule and prevent the ingestion of two doses too close together.


Q: Does Levofloxacino interact with vitamins or supplements?

Yes, the oral forms of Levofloxacino are known to interact with multivalent cations (minerals with multiple charges), which are often found in vitamins and mineral supplements, such as iron, zinc, or calcium. Regulatory information specifies that the oral dose should be separated from these products by at least two hours to support proper absorption of the medicine.


Q: What kind of infections is Levofloxacino usually prescribed for?

The drug is approved by regulators to treat a range of established bacterial infections. These typically include community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, certain complicated urinary tract infections, and sometimes specialized indications like post-exposure prophylaxis for anthrax.


Q: What are the most serious warnings associated with Levofloxacino?

The most serious warnings in regulatory documents highlight the risk of disabling and potentially irreversible serious adverse reactions affecting multiple body systems. These risks include tendon damage (tendinitis and rupture), peripheral neuropathy (nerve damage), and severe central nervous system effects, such as anxiety and confusion.


Q: Can Levofloxacino affect sleep?

Yes, according to official side effect data, trouble sleeping, also known as insomnia, is listed as a very common side effect associated with the use of Levofloxacino. This is one of the medicine's documented effects on the central nervous system (CNS).


Q: Can I take Levofloxacino with common pain relievers like Ibuprofen?

Official drug interaction documents list Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes Ibuprofen, as potential interacting agents. This is due to a theoretical increased risk of central nervous system stimulation that could potentially lead to side effects like convulsions.


Q: Can taking Levofloxacino affect blood sugar levels?

Yes, regulatory warnings note that Levofloxacino is associated with the risk of blood glucose disturbances. Both unusually low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia) have been reported, sometimes severely, and monitoring is often advised.


Q: What is the expected time frame for Levofloxacino to fully leave the system?

Official pharmacokinetic (PK) data states that in people with normal kidney function, Levofloxacino has an elimination half-life of 6 to 8 hours. Official data indicates that it can take approximately 30 to 40 hours for the medicine to be largely eliminated from the body.


Q: Does Levofloxacino change the effectiveness of birth control pills?

Official information suggests that antibiotics, including Levofloxacino, may reduce the effectiveness of certain hormonal birth control medications in some users. Users are advised to be aware of the potential for reduced efficacy.


Q: Can Levofloxacino cause psychological side effects like confusion or anxiety?

Yes, Levofloxacino has been associated with effects on the central nervous system (CNS). Official adverse reaction reports list reactions such as confusion, anxiety, nervousness, depression, hallucinations, and other changes in mood or behavior.


Q: Is Levofloxacino known to cause any issues with the liver?

Severe liver injury, also known as hepatotoxicity, has been reported in official warnings associated with Levofloxacino use. The official product information states that the medication should be stopped immediately if signs of liver damage appear.


Q: What is the official guidance regarding Levofloxacino use during pregnancy?

Official guidance states that Levofloxacino should be used during pregnancy only if the potential benefit is judged to outweigh the potential risk to the fetus. It is generally listed as contraindicated for routine use due to safety concerns.


Q: Are there specific food types or drinks that interact with Levofloxacino?

Regulatory guidance advises against taking oral Levofloxacino with food items that contain high levels of multivalent cations, such as dairy products (e.g., milk or yogurt). This is because these minerals can interfere with the drug's absorption. Some patient information also cautions against grapefruit and grapefruit juice.


Q: Do studies suggest a risk of nerve damage from Levofloxacino?

Regulatory documents carry a high-level warning regarding the risk of peripheral neuropathy, which is nerve damage in the arms or legs. This serious reaction has been described as potentially disabling and, in some cases, irreversible.


Q: Does Levofloxacino have any documented effects on driving or operating machinery?

Yes, official documents state that Levofloxacino may cause side effects like dizziness or lightheadedness, which could affect a person's coordination and judgment. Official warnings note that caution is required when performing tasks that require mental alertness, such as driving or operating machinery.


Q: Is Levofloxacino commonly used to prevent infections?

While the drug is primarily used to treat established bacterial infections, regulatory labels do list it for a specific type of preventative treatment. This is post-exposure prophylaxis for inhalational anthrax, meaning it is used after exposure to prevent the disease from developing.


Q: Is it normal for Levofloxacino to cause diarrhea?

Yes, diarrhea is listed in official documents as a very common side effect associated with the use of Levofloxacino. If diarrhea is severe or persistent, this is listed in regulatory information as a reason to seek medical evaluation.


Q: Can I consume caffeine while taking Levofloxacino?

Official interaction documents note that some antibiotics in the fluoroquinolone class may affect how the body processes caffeine. This interaction can slow the breakdown of caffeine, potentially intensifying its effects, such as increased nervousness or trouble sleeping.


Q: Are there any specific safety requirements for stopping Levofloxacino treatment?

Official guidance requires immediate discontinuation of the medicine at the first sign of a serious adverse reaction, such as tendon pain, a rash, or nerve symptoms. Otherwise, regulatory information generally describes the completion of the full prescribed course as necessary.

Advertisements

How should Levofloxacino be stored and disposed of?

How to Store and Dispose of Levofloxacino?

Official Storage Requirements

Levofloxacino should be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original, tightly closed container and protected from excessive heat, moisture, and direct light. It is essential to prevent the medication from freezing. To ensure safety, Levofloxacino must be stored in a secure location that is out of the sight and reach of children and pets.

Official Disposal Instructions

Do not keep outdated or unused Levofloxacino. For disposal, patients should follow official guidelines, such as utilizing a medicine take-back program when one is available. If a take-back program is not available, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag or container, and then discarded in the household trash. Do not flush this medicine down the toilet unless explicitly instructed by official regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levofloxacino found in:

A-Z Index: